Systematic Review Maps Strategies to Boost Macromolecular Drug and Peptide Bioavailability
Background
Despite their high safety, strong specificity, and low immunogenicity, macromolecular drugs, including peptides and proteins, face significant challenges due to inherently low bioavailability. These drugs encounter multiple physiological barriers in various delivery systems, limiting their therapeutic efficacy and broader clinical translation. Current standard-of-care often struggles with efficient and targeted delivery, leading to suboptimal drug concentrations at target sites. A comprehensive synthesis of strategies to overcome these absorption barriers and enhance bioavailability has been critically lacking, hindering the design of advanced drug delivery systems.
Study Design
This article presents a systematic review summarizing the diverse strategies aimed at enhancing the bioavailability of macromolecular drugs. Researchers analyzed existing literature to identify and categorize the multiple absorption barriers encountered by peptides and proteins across different delivery systems. The review then detailed technical approaches developed to overcome these delivery challenges, focusing on methods to improve drug absorption and stability. The overarching goal was to provide a theoretical framework and foundational reference for the design of novel macromolecular drug delivery systems.
Results
The review comprehensively mapped the significant absorption barriers impeding macromolecular drug delivery, including enzymatic degradation, poor membrane permeability, and rapid systemic clearance. It then synthesized a range of strategies to circumvent these obstacles, highlighting advancements in formulation science and chemical modification. Key approaches discussed include the use of various biological carriers such as nanoparticles, liposomes, and hydrogels, which protect drugs from degradation and facilitate targeted delivery. Chemical modifications like PEGylation were also noted for improving stability and prolonging circulation time. The review emphasized how these enhanced delivery systems enable novel therapeutic applications.
Notably, improved delivery systems for macromolecular drugs, particularly those prepared through biotechnology, can be combined with biological carriers to activate the immune system, inducing the production of immune cells and factors for disease prevention and treatment.
Key Findings
- Identified enzymatic degradation, poor membrane permeability, and rapid clearance as primary barriers to macromolecular drug bioavailability.
- Summarized strategies including biological carriers (nanoparticles, liposomes) to protect drugs and facilitate targeted delivery.
- Detailed chemical modification techniques (e.g., PEGylation) for enhancing drug stability and circulation time.
- Highlighted how improved delivery systems enable immune system activation for disease prevention and treatment.
- Provided a theoretical foundation for designing novel macromolecular drug delivery systems.
Why It Matters
This review provides a crucial roadmap for researchers and developers in the peptide and biotech space, offering a consolidated view of effective strategies to overcome bioavailability hurdles. For peptide users and biohackers, understanding these delivery mechanisms is key to optimizing administration protocols and maximizing therapeutic outcomes. The insights can guide the selection of appropriate carriers or modification techniques when designing novel peptide formulations, potentially leading to more stable, potent, and targeted interventions. This work accelerates the translation of promising peptide candidates from lab to clinic by providing a foundational reference for developing more efficient and patient-friendly delivery systems, moving closer to usable protocols for a wider range of macromolecular therapeutics.
macromolecular-drugs
peptides
bioavailability
drug-delivery
formulation
biological-carriers